Stefanes Natália Marcéli, Cunha-Silva Maria Eduarda, de Oliveira Silva Lisandra, Walter Laura Otto, Santos-Silva Maria Cláudia, Gartia Manas Ranjan
Department of Mechanical and Industrial Engineering, Louisiana State University, Baton Rouge, LA, United States.
Post-Graduation Program in Pharmacy, Health Science Center, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Int Rev Cell Mol Biol. 2025;391:1-41. doi: 10.1016/bs.ircmb.2024.08.007. Epub 2024 Sep 5.
Cancer presents a significant challenge to global health, driving worldwide concerted efforts to advance early detection, predict therapeutic response, and identify novel targeted therapies. Liquid biopsies emerge as promising avenues for discerning cancer biomarkers, offering less invasive approaches compared to conventional methods. Utilizing increasingly robust technologies, diverse bodily fluids can unveil genetic variants, epigenetic modifications, transcriptional alterations, and metabolomic signatures associated with cancer, thereby furnishing valuable insights for clinical management. This chapter intends to review the sources of cancer-related biomarkers found in circulation, prevalent techniques utilized for their identification, and the potential implications of different biomarker types on the management of cancer. Certain biomarkers currently used in clinical practice will be addressed, as well as potential biomarkers still in the study phase, and the inherent challenges in their practical implementation.
癌症对全球健康构成重大挑战，促使全球共同努力推进早期检测、预测治疗反应并确定新型靶向治疗方法。液体活检作为识别癌症生物标志物的有前景的途径出现，与传统方法相比提供了侵入性较小的方法。利用日益强大的技术，多种体液可以揭示与癌症相关的基因变异、表观遗传修饰、转录改变和代谢组学特征，从而为临床管理提供有价值的见解。本章旨在综述循环中发现的癌症相关生物标志物的来源、用于其识别的常用技术，以及不同类型生物标志物对癌症管理的潜在影响。将讨论目前临床实践中使用的某些生物标志物，以及仍处于研究阶段的潜在生物标志物，以及它们实际应用中固有的挑战。
